Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Receivables Refunds (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Receivables Refunds data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Receivables Refunds fell 93.94% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 93.94%, while the annual FY2025 figure was $2.0 million, 93.94% down from the prior year.
  • Receivables Refunds reached $2.0 million in Q4 2025 per INDV's latest filing, down from $13.0 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $33.0 million in Q4 2024 and bottomed at $2.0 million in Q4 2025.
  • Average Receivables Refunds over 4 years is $15.8 million, with a median of $13.0 million recorded in 2021.
  • Peak YoY movement for Receivables Refunds: plummeted 61.54% in 2022, then crashed 93.94% in 2025.
  • A 4-year view of Receivables Refunds shows it stood at $13.0 million in 2021, then tumbled by 61.54% to $5.0 million in 2022, then soared by 560.0% to $33.0 million in 2024, then plummeted by 93.94% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables Refunds were $2.0 million in Q4 2025, $13.0 million in Q3 2025, and $29.0 million in Q1 2025.